FDA panel backs Biosense Webster's catheter for atrial fibrillation
This article was originally published in Clinica
A US FDA advisory panel has unanimously recommended approval of an ablation catheter developed by Biosense Webster for the treatment of atrial fibrillation (AF). The FDA is not required to follow the panel's advice, though it usually does.
You may also be interested in...
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.
Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.